StemCell Therapy

BELGRADE, Mont., April 24, 2012 /PRNewswire/ -- BacterinInternational Holdings, Inc. (BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will release its financial results for the three months ended March 31, 2012 after the close of regular market trading on Thursday, May 3, 2012. A conference call will follow at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Conference Call Details:

Date: Thursday, May 3, 2012 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Dial-In Number: 1-877-941-1429 International: 1-480-629-9857 Conference ID#: 4535021

The conference call will be broadcast simultaneously and available for replay here and at the investor section of the company's Web site at http://www.bacterin.com/index.htm.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Hayden IR at 1-646-755-7412.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day and until June 3, 2012.

Replay number: 1-877-870-5176 International replay number: 1-858-384-5517 Replay pin number: 4535021

About Bacterin International Holdings Bacterin International Holdings, Inc. (BONE) develops, manufactures and markets biologics products to domestic and international markets.Bacterin's proprietary methods optimize the growth factors in humanallografts to create the ideal stem cell scaffold to promote bone,subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery andsubchondral repair in knee and other joint surgeries.

Bacterin'sMedical Device division develops, employs, and licenses bioactive coatings for various medical device applications.Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibitbiofilm formation and microbial contamination. For further information, please visit http://www.bacterin.com.

Important Cautions Regarding Forward-looking Statements This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Link:
Bacterin International Holdings, Inc. Schedules First Quarter 2012 Financial Earnings Conference Call

This entry was posted on April 25, 2012 at 7:15 pm and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |